Cervical Cancer Treatment Market

Cervical Cancer Treatment Market by Types (Squamous Cell Carcinoma, Adenocarcinoma, and Adenosquamous Carcinoma), Products (Prevention [Gardasil/Gardasil9 and Cervarix], Treatment [Avastin, Keytruda, Generics, and Others]), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1003
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 145
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global cervical cancer treatment market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of cervical cancer, favorable government initiatives and introduction of targeted treatments.

Cervical cancer is a kind of cancer that develops in the cervix. The cervix is a hollow cylinder that links a woman's uterus to her vaginal canal. The majority of cervical cancers start in cells on the cervix's surface. Cervical cancer used to be a significant cause of mortality among women in the US. Since screening tests become widely available, this has improved. Many women with cervical cancer are unaware that they have it until it has progressed to the point where symptoms appear. When symptoms do appear, they are frequently misinterpreted as menstrual cycles or urinary tract infections (UTIs). Unusual bleeding, such as between periods, after sex, or after menopause, vaginal discharge that looks or smells different than usual, pain in the pelvis, a need to urinate more frequently, and pain while urination are all common cervical cancer symptoms. The sexually transmitted human papillomavirus (HPV) is responsible for the majority of cervical cancer cases. The virus that causes genital warts is the same one that causes this. There are over 100 distinct HPV strains. Cervical cancer is caused by just a few kinds. HPV-16 and HPV-18 are the two most prevalent kinds that cause cancer. Cervical cancer is not inevitable if you are infected with a cancer-causing strain of HPV. The vast majority of HPV infections are cleared by your immune system within two years.

Global Cervical Cancer Treatment Market Summary

Doctors use a Pap smear test to diagnose cervical cancer. To do this test, the doctor takes a sample of cells from the patient's cervix's surface. These cells are then submitted to a lab for precancerous or cancerous changes to be examined for. If these changes are identified, the doctor may recommend a colposcopy, which is a technique for checking the cervix of the patient. A biopsy, which is a sample of cervical cells, may be taken during this examination. After a cancer diagnosis, the doctor will give a stage to the patient's cancer. The stage indicates whether or not the cancer has spread and, if so, how far it has spread. Patients' cancer is staged to help doctors select the best treatment for them. Cervical cancer can be successfully treated if detected early. Surgery, radiation therapy, chemotherapy, and targeted therapy are the four primary therapies. These therapies are sometimes combined to improve their efficacy. Human immunodeficiency virus (HIV), chlamydia, smoking, obesity, a family history of cervical cancer, a low-fiber diet, using birth control pills, having three full-term pregnancies, and being younger than 17 when you got pregnant for the first time are all risk factors for developing cervical cancer.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing prevalence of human immunodeficiency virus in women is projected to boost the market growth during the forecast period.
  • Increasing demand for early diagnosis and treatment of cervical cancer are anticipated to drive the market growth in the coming years.
  • Technological advancements of targeted therapies and favorable government initiatives are estimated to fuel the market growth.
  • Lack of awareness, adverse effects associated with cancer therapy and other misconceptions about cervical cancers is projected to hamper the market growth during the forecast period.
  • High cost of treatment is anticipated to hinder the market growth during the forecast period.
  • Increased R&D investment in oncologic diseases segment is expected to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global cervical cancer treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Cervical Cancer Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Squamous Cell Carcinoma, Adenocarcinoma, and Adenosquamous Carcinoma), Products (Prevention [Gardasil/Gardasil9 and Cervarix], Treatment [Avastin, Keytruda, Generics, and Others]), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

F. Hoffmann-LA Roche AG; Merck & Co., Inc.; GlaxoSmithKline PLC; Allergan PLC; Pfizer, Inc.; Biocon Ltd.; Bristol-Myers Squibb; AstraZeneca PLC; and Eli Lilly & Co. Merck & Co.

 

Market Segment Insights

Squamous cell carcinoma segment is expected to account for a key share
Based on types, the cervical cancer treatment market is segmented into squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma. The squamous cell carcinoma segment is expected to account for a key share of the market during the forecast period owing to its increased prevalence. If left untreated, high-grade squamous intraepithelial lesion (HSIL) of the cervix can develop to squamous cell carcinoma (SCC). Screening using Pap tests on a regular basis aids in the early detection and diagnosis of SCC. Adenocarcinoma of the cervix is more common in certain ethnic groups, such as Hispanic and African-American women. The histology, as seen under a microscope, is used to distinguish between SCC and adenocarcinoma. Cervical adenosquamous carcinoma is the most uncommon form, affecting both squamous and glandular tissues.

Global Cervical Cancer Treatment Market By Type

Gardasil segment is expected to hold a key share
Based on product, the cervical cancer treatment market is bifurcated into prevention, and treatment. The prevention segment is further sub segmented into gardasil/gardasil 9 and cervarix. The treatment segment is further sub segmented into avastin, keytruda, generics, and others. The gardasil segment is expected to hold a key share of the market during the forecast period owing to increased sales around the world. In addition, the FDA authorized Gardasil 9 in 2015, which is a modified, nonavalent form of Gardasil. Gardasil (quadrivalent) and Gardasil 9 (nonavalent) gained a significant clinical advantage over Cervarix as a result of this label extension (bivalent). Cervarix was withdrawn from the US market by GlaxoSmithKline in 2016 owing to poor demand and fierce competition. Although generic medicines continue to dominate the market, biologics and other targeted treatments are expected to bring in a paradigm change in this therapeutic area during the forecast period.

Hospital pharmacies segment is expected to constitute a key share
Based on distribution channel, the cervical cancer treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to constitute a key share of the market during the forecast period owing to increasing consumer awareness and increased healthcare expenditure. Cervical cancer products are kept in stock at hospital pharmacies for both out-patients and in-patients.

On the other hand, the online pharmacies segment is anticipated to expand at a rapid pace during the forecast period owing to its convenience offered in terms of price, access and delivery and the user-friendly interface. Furthermore, they provide a variety of discounts for purchases above a specific amount, as well as bundle prices for cancer products.

Global Cervical Cancer Treatment Market By Distribution Channel

North America is anticipated to dominate the market
On the basis of regions, the Cervical Cancer Treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing cancer prevalence, increased consumer awareness, and technological advancements in the diagnosis and treatment of oncological diseases. The regional market is being driven by an increase in the number of health initiatives undertaken by private and public sector organizations, as well as the use of more advanced technology.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to growing population, increasing disease prevalence, and demand for cost-effective treatments. Biosimilars' growing popularity in emerging countries like India and China might change the therapeutic landscape in the region.

Global Cervical Cancer Treatment Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cervical Cancer Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cervical Cancer Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cervical Cancer Treatment Market - Supply Chain
  4.5. Global Cervical Cancer Treatment Market Forecast
     4.5.1. Cervical Cancer Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cervical Cancer Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cervical Cancer Treatment Market Absolute $ Opportunity
5. Global Cervical Cancer Treatment Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Cervical Cancer Treatment Market Size and Volume Forecast by Types
     5.3.1. Squamous Cell Carcinoma (SCC)
     5.3.2. Adenocarcinoma
     5.3.3. Adenosquamous Carcinoma
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cervical Cancer Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Cervical Cancer Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Cervical Cancer Treatment Demand Share Forecast, 2019-2026
7. North America Cervical Cancer Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Cervical Cancer Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Cervical Cancer Treatment Market Size and Volume Forecast by Types
     7.4.1. Squamous Cell Carcinoma (SCC)
     7.4.2. Adenocarcinoma
     7.4.3. Adenosquamous Carcinoma
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Cervical Cancer Treatment Demand Share Forecast, 2019-2026
8. Latin America Cervical Cancer Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Cervical Cancer Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Cervical Cancer Treatment Market Size and Volume Forecast by Types
     8.4.1. Squamous Cell Carcinoma (SCC)
     8.4.2. Adenocarcinoma
     8.4.3. Adenosquamous Carcinoma
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Cervical Cancer Treatment Demand Share Forecast, 2019-2026
9. Europe Cervical Cancer Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Cervical Cancer Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Cervical Cancer Treatment Market Size and Volume Forecast by Types
     9.4.1. Squamous Cell Carcinoma (SCC)
     9.4.2. Adenocarcinoma
     9.4.3. Adenosquamous Carcinoma
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Cervical Cancer Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Cervical Cancer Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Cervical Cancer Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Cervical Cancer Treatment Market Size and Volume Forecast by Types
     10.4.1. Squamous Cell Carcinoma (SCC)
     10.4.2. Adenocarcinoma
     10.4.3. Adenosquamous Carcinoma
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Cervical Cancer Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Cervical Cancer Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Cervical Cancer Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Cervical Cancer Treatment Market Size and Volume Forecast by Types
     11.4.1. Squamous Cell Carcinoma (SCC)
     11.4.2. Adenocarcinoma
     11.4.3. Adenosquamous Carcinoma
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Cervical Cancer Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Cervical Cancer Treatment Market: Market Share Analysis
  12.2. Cervical Cancer Treatment Distributors and Customers
  12.3. Cervical Cancer Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. F. Hoffmann-LA Roche AG
     12.4.2. Merck & Co., Inc.
     12.4.3. GlaxoSmithKline PLC
     12.4.4. Allergan PLC
     12.4.5. Pfizer, Inc.
     12.4.6. Biocon Ltd.
     12.4.7. Bristol-Myers Squibb
     12.4.8. AstraZeneca PLC
Segments Covered in the Report
The global Cervical Cancer Treatment market has been segmented on the basis of

Types
  • Squamous Cell Carcinoma (SCC)
  • Adenocarcinoma
  • Adenosquamous Carcinoma
Products
  • Prevention
    • Gardasil/Gardasil9
    • Cervarix
  • Treatment
    • Avastin
    • Keytruda
    • Generics
    • Others
Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • F. Hoffmann-LA Roche AG
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • Allergan PLC
  • Pfizer, Inc.
  • Biocon Ltd.
  • Bristol-Myers Squibb
  • AstraZeneca PLC
  • Eli Lilly & Co. Merck & Co.

Key players competing in the Cervical Cancer Treatment market are F. Hoffmann-LA Roche AG; Merck & Co., Inc.; GlaxoSmithKline PLC; Allergan PLC; Pfizer, Inc.; Biocon Ltd.; Bristol-Myers Squibb; AstraZeneca PLC; and Eli Lilly & Co. Merck & Co.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, in January 2019, Celgene was acquired for $74 billion by Bristol-Myers Squibb, an American biopharmaceutical firm. With this acquisition, Bristol-Myers Squibb will be able to maintain a strong presence in the cancer, immunology, inflammatory, and cardiovascular disorders medication markets.

Global Cervical Cancer Treatment Market By Key Players

Buy Report